Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Risperidone in MDD Non-Responders
NCT00095134Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of risperidone in major depressive disorder (MDD), sponsored by Johnson & Johnson. Started Oct 2004; status: completed.
02
Drugs
risperidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00095134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095134.